Find a Clinical Trial

Showing 21 - 30 of 168 Trials

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma

Principal Investigator:

Brian Peter Marr, MD

Contact Number:

212-342-5162

NCT Number:

NCT06007690

Population:

Adult

Phase:

III

The purpose of this study is to test and determine how safe and how well bel-sar treatment works compared to sham (no medication or laser) in participants who have a type of eye cancer called an indeterminate lesion (a growth in your eye that is suspected to be melanoma) or choroidal melanoma, also known as eye melanoma. We hope that Bel-sar can selectively target and destroy the tumor cells in the eye, while not affecting the normal cells. Bel-sar has not been approved by Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) must be 18 years old or older - must not have...
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Principal Investigator:

Benjamin Izar, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07015190

Population:

Adult

Phase:

III

The study drug used in this study is darovasertib. The study drug will be given to you orally (by mouth) if you participate in the study. You should only take the study drug as instructed. Darovasertib is an investigational (experimental) new drug, which means darovasertib has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authorities in the world. Darovasertib blocks a protein in your body called Protein Kinase C (PKC). Approximately 90% of people with uveal melanoma have a genetic mutation in PKC. The tumor may depend on the effects of PKC to...
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

Principal Investigator:

Monica Kasbekar, MD PHD

Contact Number:

212-342-5162

NCT Number:

NCT07357727

Population:

Adult

Phase:

III

The purpose of this study is to find out whether taking pelabresib together with ruxolitinib works better than taking ruxolitinib alone in adults with myelofibrosis, a rare blood cancer that affects the bone marrow. Ruxolitinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of myelofibrosis, while pelabresib is an investigational drug that has not been approved by the FDA. The study will compare whether the combination treatment can better reduce spleen size and improve myelofibrosis-related symptoms than ruxolitinib alone. Participants will be randomly assigned...
A Multinational, Multicenter, Prospective, OpenLabel, Safety and DosimetryStudy of Lutetium-177 (177Lu)Rosopatamab Tetraxetan in Combination withStandard of Care in Patients with Prostate-SpecificMembrane Antigen (PSMA) Positive MetastaticCastration

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT06520345

Population:

Adult

Phase:

III

This study aims to explore a possible new treatment for advanced prostate cancer that has spread to other parts of the body and tests positive for a specific protein called PSMA (prostate-specific membrane antigen). This treatment involves a special drug that seeks out cancer cells by recognizing PSMA on their surface. The drug combines an antibody— a molecule that can find and attach to specific targets on cancer cells—with a radioactive component. Once attached, it delivers radiation directly to the cancer cells to help destroy them. The drug being studied is called 177Lu-TLX591...
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Principal Investigator:

Rajshekhar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT03937635

Population:

Adult

Phase:

III

The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period of time in which patients are free of multiple myeloma symptoms differs between the two treatment groups. Daratumumab is already approved by the FDA for use in combination with lenalidomide and dexamethasone in people who have received at...
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

Principal Investigator:

Claire Sathe, MD

Contact Number:

212-342-5162

NCT Number:

NCT06492616

Population:

Adult

Phase:

III

The purpose of this study is to test a new endocrine therapy, called elacestrant, that may stop hormones from attaching to cancer cells and helping them grow. Researchers would like to understand if switching standard treatment to elacestrant (the study drug) will help to slow down or stop the growth of cancer. Treatments for early breast cancer include endocrine therapy, also called hormone therapy. Endocrine therapies work by blocking hormones from reaching the cancer cells or by reducing the amount of hormones the body makes. Are you Eligible? (Inclusion Criteria) Must be 18 years old or...
FURMO-006 // A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced

Principal Investigator:

Catherine Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT07185997

Population:

Adult

Phase:

III

You are being asked to participate in this study because you have a type of lung cancer called non-small-cell lung cancer (NSCLC) that has spread and because it contains certain mutations (changes) in a gene called epidermal growth factor receptor (EGFR). The EGFR mutations lead to cancers in the lung such as NSCLC. This study is for people with uncommon EGFR mutation subtypes where the data for the best treatment is less known due to their rarity. A drug called firmonertinib is being developed for the treatment of NSCLC with mutations in EGFR with a specific change in the P-loop and alpha C-...
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT06671912

Population:

Adult

Phase:

III

This study is being done to answer the following question: Is treatment with a lower dose of tamoxifen, a form of hormonal therapy, as good as the usual hormonal therapy in women with low-risk, early-stage breast cancer? The usual approach for patients who are not in a study is treatment with hormonal therapy. Hormonal therapy can be an aromatase inhibitor (such as letrozole, anastrozole, or exemestane) or tamoxifen at a dose of 20mg/day. Your doctor can explain which treatment may be best for you. For patients who get the usual approach for this cancer, about 96 out of 100 are free of cancer...
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Principal Investigator:

Meghna S Trivedi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05812807

Population:

Adult

Phase:

III

This study is being done to answer the following question: Among patients with early-stage triple-negative breast cancer (TNBC) who achieve a pathologic complete response (pCR) after preoperative chemotherapy in combination with pembrolizumab, will observation after surgery be as effective as completing 6 more months of pembrolizumab after surgery at preventing cancer from coming back? This study aims to find out if observation is as good as the usual approach for early-stage TNBC. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab...
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab inCombination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary TractCancer (ARTEMIDE-Biliary02)

Principal Investigator:

Aiwu R He, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT07221253

Population:

Adult

Phase:

III

The purpose of this study is to understand the effectiveness and safety of rilvegostomig in combination with chemotherapy to that of standard treatment for advanced biliary tract cancer (durvalumab in combination with gemcitabine and cisplatin). We are also performing this study to better understand advanced biliary tract cancer and associated health problems. Rilvegostomig has not been approved by the Food and Drug Administration (FDA). Durvalumab, gemcitabine, and cisplatin are FDA approved to treat biliary tract cancer, but the combination of rilvegostomig, gemcitabine, and cisplatin is...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages